Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The value of the global recombinant vaccine market was USD 14.91 billion in 2023, driven by the technological advancements in vaccine development across the globe. The market value is expected to grow at a CAGR of 11.9% during the forecast period of 2024-2032 to reach a value of USD 41.04 billion by 2032.
Recombinant vaccines are vaccines made with DNA recombination, primarily based on yeast or bacterial cells that are embedded into the host cell to trigger an immune response. Some examples of recombinant vaccines are vaccines against meningitis, hepatitis B, and Influenza B diseases. Recombinant vaccines are less risky, can be produced easily and are also capable of being inserted into multiple carriers.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market can be bifurcated into live attenuated and subunit. By disease indication, the market is divided into hepatitis B, rotavirus, herpes zoster, and meningococcal B, among others. On the basis of end use, the market is segmented into paediatrics, adults, and veterinary. By region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global recombinant vaccines market covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Subunit types of recombinant vaccines are expected to hold a substantial share in the recombinant vaccines market because it does not contain whole virus or bacteria. Containing specific antigens helps these vaccines focus on a small number of antigens. It might require the person to take repeated doses but is considered safer to use in comparison to live attenuated vaccine.
Live attenuated recombinant vaccines contain weakened forms of the virus they protect against. Although they provide long-lasting effects, they may not be suitable for people with weak immune systems. In people with weak immune systems, live attenuated recombinant vaccines risk causing the disease.
Adult end users are a leading shareholder in the recombinant vaccines market because of increasing number of adult patients that are proactively protecting themselves from infectious diseases. This has increased the demand for recombinant vaccine to protect against diseases other vaccine do not prevent, thereby increasing its production. Due to the strong nature of recombinant vaccines, it is safer to give them to adults that can monitor and report any side effects, and have relatively stronger immune systems as compared to children. With new recombinant vaccines released, adults have a wider option to choose from.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
GSK plc is pharmaceutical and biotechnology company that has its headquarter in Brentford, United Kingdom. It was founded in 2000 and manufactures specialty medicines along with innovative vaccines for the prevention and treatment of diseases.
Pfizer Inc. founded in 1849 is headquartered in New York, United States. It is a specialised biotechnology and pharmaceutical company that develop and sell vaccines, medical devices, medicines, and healthcare products for treating diseases.
Sanofi was established in 2004 and is based out of Paris, France. A pharmaceutical and healthcare company, it aims to fulfil the health needs of people. They manufacture and sell various health products including vaccines and medicines.
Other market players include Walvax Biotechnology Co., Ltd. (Walvax), and Dynavax Technologies Corporation, among others.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Disease Indication |
|
Breakup by Distribution Channel |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
The global market size for recombinant vaccines reached a value of more than USD 14.91 billion in 2023.
The market is expected to grow at a CAGR of 11.9% between 2024 and 2032.
The major market drivers include increasing awareness, improved availability of recombinant vaccines, and spread of infectious diseases.
The global market size for recombinant vaccines is expected to reach a value of more than USD 41.04 billion by 2032.
The key trends of the market are advantages of recombinant vaccines, research and development by key players, and reduced expenditure and side effects of these vaccines.
Key market players include GSK plc, Pfizer Inc., Sanofi, Walvax Biotechnology Co., Ltd. (Walvax), and Dynavax Technologies Corporation, among others.
Recombinant vaccines are made with DNA recombination of yeast or bacterial cells that are embedded into the host cell to trigger an immune response.
Some examples of recombinant vaccines are vaccines against meningitis, hepatitis B, and Influenza B diseases.
The global recombinant vaccines market is segmented based on type, disease indication, end use, and region.
Recombinant vaccines are less risky, can be produced easily and are also capable of being inserted into multiple carriers.
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Pricing Plans
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-120-433-0800
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124